10/03/2019 - 19:50

Revenue generating biotech Koligo eyes ASX listing

10/03/2019 - 19:50

Bookmark

Save articles for future reference.

With a breakthrough product that is already generating revenue and more products in the pipeline, regenerative medicine company Koligo Therapeutics is pitching its unique offering ahead of a proposed $6m listing on the ASX. Its “Kyslecel” product for patients suffering from chronic or acute recurrent pancreatitis has already been used for 22 procedures since commercial sales started in November 2017.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options